Paul Defranco

Paul Defranco practices at Lincoln Park Care Center in Lincoln Park, New Jersey.

Paul Defranco's NPI, 1952453839, was assigned on January 18, 2007. Paul Defranco graduated from Kansas City University of Medicine and Biosciences College of Osteopathic Medicine in 2000. Paul Defranco holds New Jersey license 25MB08195300.

Paul Defranco's primary practice is Lincoln Park Care Center, at 499 Pine Brook Road, Lincoln Park, NJ 07035 in Morris County. The practice phone is (973) 696-3300.

Paul Defranco's primary practice is Lincoln Park Care Center in Lincoln Park, New Jersey. Paul Defranco is also affiliated with St. Joseph's University Medical Center. The medical group on file is Allied Medical Associates. Dmand AI also links Paul Defranco to 1 more hospital, 1 group practice or clinic, 1 home health agency and 1 skilled nursing facility, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Paul Defranco practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Paul Defranco's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Paul Defranco is licensed in New Jersey.

CMS data shows 5,649 Medicare services from Paul Defranco across 15 procedure codes in 2024, for 561 Medicare patients. Medicare paid $500,466 for them.

CMS counts 561 Medicare patients who saw Paul Defranco in 2024. The largest group is 75 to 84, with 189 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 39% are also on Medicaid. Their average risk score is 2.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Paul Defranco's median patient age at 71, with 47% women.

In 2024, Paul Defranco wrote 2,501 Medicare Part D claims for 270 patients. 87% of them were for generic drugs. CMS names the drug for 2,016 of them, across 63 drugs with 11 or more claims each, at $101,464 in total drug cost. In 2023, CMS named 2,010 claims across 67 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Paul Defranco for performance year 2024, reported as part of a group. Paul Defranco accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Paul Defranco as offering telehealth. CMS counts 790 procedures of removal of tissue by Paul Defranco, more than 98% of the clinicians it reports for that procedure.

CMS Open Payments shows 102 general payments to Paul Defranco from 33 drug and device companies from 2016 to 2022. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $189.

Paul Defranco graduated from Kansas City University of Medicine and Biosciences College of Osteopathic Medicine in 2000.